Melbourne-based biotech firm PolyActiva, which has spent 15 years developing an eye-implant technology to treat glaucoma, has won a $27 million investment from the National Reconstruction Fund Corporation as part of a $40 million Series C round. The NRFC’s $27 million commitment was a part of PolyActiva’s $40 million Series C round, with the investment…

The post Melbourne biotech PolyActiva scores $27m NRFC investment appeared first on InnovationAus.com.